Immuno-oncology is the science of manipulating immune system’s natural ability to fight cancer. It has been under evaluation for more than a century, but only recently has it entered a renaissance phase with approval of multiple agents use in different cancer types. Recent breakthroughs in the field have changed the treatment paradigm for many types of cancer. In this seminar, we will review the evidence of clinical outcomes of immuno-oncology use with a focus on checkpoint inhibitors.

**Learning Objectives:**

1. Explain the properties of immunotherapy in cancer therapeutics
2. List and give examples of the major classes of cancer immunotherapy
3. Describe the mechanisms of action of checkpoint inhibitors
4. Evaluate the evidence of key clinical outcomes associated with checkpoint inhibitors use in selected clinical trials

Wendy graduated with a BSc (Pharmacy) Hons from NUS. She completed her pre-registration training at National University Hospital (NUH) and she is a registered pharmacist. She is currently a Pharmacy Resident with NUH Pharmacy Post-Graduate Year 1 (PGY-1) Residency Programme and pursuing her Masters in Clinical Pharmacy with University of South Australia (UNISA).